R&D expert joins board of Genomics
Dr Jose-Carlos Gutiérrez-Ramos, previously Pfizer's senior vice president and global head of BioTherapeutics R&D, has been appointed to the board of Oxford-based Genomics.
The pioneering healthcare firm, which uses genetic information to develop innovative precision healthcare tools, said the appointment will support its rapid growth and strengthen its offering globally, with a focus on scaling its life sciences business.
Gutiérrez-Ramos, who started his career as assistant professor of genetics at Harvard medical school, has held senior roles in the world’s largest pharmaceutical companies.
He was also previously Head of Drug Discovery at Abbvie, and at Pfizer, he led the biologics platform from early discovery to early manufacturing, spearheaded 25 novel programmes in drug discovery and development.
He also and founded the Center for Therapeutic Innovation. Before that, he served as Senior Vice President and Head of the Immunoinflammation Center for Drug Discovery at pharma giant GlaxoSmithKline.
He is currently the chief science officer at Danaher Corporation.
Simon Dingemans, chairman of the board at Genomics, said: "His extensive experience in life sciences R&D across biotechs and pharma companies will help strengthen our offering to both existing and new biopharma clients of tools to allow them to accelerate and differentiate their drug discovery and development programmes.
"Genomics continues to grow at a rapid pace, serving some of the biggest names across life sciences, health systems, and insurance.
"2025 is an exceptionally exciting year for the organisation, after a record-breaking 2024 that has put Genomics right at the heart of the drive to change the future of healthcare through the widespread adoption of genomics."
The genomics industry is forecast to reach over US$ 164.2 billion by 2032, fueled by the need to improve the prevention of common, chronic diseases.
In the next 5-10 years, genomics is set to become the gold-standard across the life sciences, insurance, and health services industries, the company said.
Dr Gutiérrez-Ramos noted: "I strongly believe genomics will be increasingly recognised as essential for drug discovery, both in identifying novel targets and the right patient populations.
"Genomics is ahead of the curve and a pioneer in this space, already working with major players in the biotech and pharmaceutical space. I am delighted to have the opportunity to join their board."
The announcement comes as Genomics is attending the J.P. Morgan Healthcare Conference 2025 in San Francisco, USA.
The company collaborates with some of the world's leading organizations including GSK, Vertex, MassMutual and Bupa, across the UK and US, helping them to predict, prevent, treat and cure disease using its proprietary algorithms and databases
